A research team, affiliated with UNIST has unveiled soft self-standing protein hydrogels that selectively deliver drugs, ...

Patients with CLE who have specific patient characteristics may have lower treatment response than patients who do not have these characteristics.

Curium, a world leader in nuclear medicine, today announced that in Estonia, Finland, Latvia, and Sweden, PYLCLARI® is now available for patients with prostate cancer. PYLCLARI® (INN: Piflufolastat (1 ...